SURFACE LOGIX ANNOUNCES THE APPOINTMENT OF BRIDGET McCARTHY, Ph.D., AS VICE PRESIDENT OF CHEMISTRY
BOSTON, Mass. (June 28, 2006) – Surface Logix
announced today the appointment of Dr. Bridget
McCarthy as Vice President of Chemistry. As a
member of the management team, Dr. McCarthy will be
responsible primarily for directing all chemistry
activities at Surface Logix.
“I am
extremely pleased to welcome Bridget to the Surface
Logix management team. Dr. McCarthy brings over 10
years of Pharmaceutical experience to Surface Logix.
She has managed research and discovery teams, has
extensive experience developing leads into drug
candidates and is well versed in the areas of medicinal
chemistry, parallel chemistry and laboratory
automation,” said Dr. Paul Sweetnam, CSO of Surface
Logix. “Bridget’s background in metabolic and
inflammatory disease as well as drug discovery and
laboratory technology will allow Surface Logix, Inc. to
further accelerate our research programs.”
Prior to
joining Surface Logix, Dr. McCarthy served as associate
director of chemistry at Pfizer Research Technology
Center in Cambridge, MA.
In this role Dr. McCarthy was responsible for managing
medicinal and analytical chemistry in support of various
drug discovery programs including targets in the areas
of obesity, diabetes and inflammation. Prior to joining
the Pfizer Cambridge site in 2001, Dr. McCarthy held the
position of Project Leader in the Veterinary Medicine
Research and Discovery Division in Groton, CT where she
actively pursued the development of anti-obesity agents
and was a key contributor to the discovery of
Dirlotapide. Dr. McCarthy has a Ph.D. in organic
chemistry from Brandeis University and conducted
post-doctoral work in asymmetric catalysis at Boston
College.
About
Surface Logix Inc.
Surface
Logix Inc. uses its expertise in biophysical chemistry
to create new small molecule drugs that are optimized to
meet the challenges of human physiology. The company is
advancing multiple internal programs focused primarily
on cardiovascular, metabolic, inflammatory and fibrotic
diseases. For more information, please visit
www.surfacelogix.com.
Contact:
David H. Donabedian, Ph.D.
Surface Logix Inc.
Vice President, Business Development
617.746.8520 |
